BAYRY vs GEHC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BAYRY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAYRY and GEHC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAYRY and GEHC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bayer AG is a Leverkusen-based life sciences company with three divisions. Crop Science (seeds, traits and crop protection, much of it inherited from the ~$63 billion Monsanto acquisition in 2018) is the largest by sales. Pharmaceuticals sells prescription drugs such as the anticoagulant Xarelto, the prostate cancer drug Nubeqa, the kidney and heart drug Kerendia, the eye drug Eylea outside the US, and the menopause treatment Lynkuet (elinzanetant). Consumer Health sells over-the-counter brands including Aspirin, Aleve, Claritin, Bepanthen and One A Day. Group sales were ~EUR 45.6 billion (~$51 billion) in 2025, and the primary listing is on Xetra in Frankfurt under BAYN, where it is a DAX member. BAYRY is a sponsored ADR that trades over the counter in the US, with four ADRs representing one ordinary share.

Full BAYRY guide

GE HealthCare is the medical technology business spun off from the former General Electric conglomerate as an independent company. It is one of the world's largest makers of medical imaging and diagnostic equipment. Its product portfolio spans MRI, CT, X-ray, ultrasound, and molecular imaging systems, plus contrast agents and radiopharmaceuticals used in scans, patient monitoring devices, and a growing suite of healthcare software and AI tools that help clinicians interpret images and manage care. GE HealthCare makes money by selling these large imaging systems to hospitals and clinics, and importantly through recurring revenue from service contracts, maintenance, software, and consumables like contrast media. With a large installed base of equipment worldwide, the company benefits from steady demand for diagnostics, an aging global population, and the growing role of AI in radiology. Headquartered in Chicago, it serves healthcare providers across developed and emerging markets and competes among the top global medical imaging vendors.

Full GEHC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BAYRY drivers: Closing out the Roundup litigation; Crop Science margin recovery.
• GEHC drivers: Large installed base and recurring revenue; AI and software in imaging.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework. For GEHC, gE HealthCare sells capital equipment to hospitals, whose budgets can tighten during economic or fiscal pressure, delaying purchases.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BAYRY if you believe its drivers more; GEHC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAYRY and GEHC guides.

BAYRY. At ~EUR 44 a share, Bayer trades at roughly 9 to 11 times its 2026 core EPS guidance and around 7 to 8 times enterprise value to EBITDA before special items, a discount to large European pharma and agrochemical peers that reflects leverage and residual litigation risk. Reported net income has been negative (a net loss of ~EUR 3.6 billion in 2025, driven by litigation provisions), so trailing P/E figures on data sites can look meaningless or distorted. The dividend has been EUR 0.11 per share, a yield well under 1%, while cash goes to settlements and debt reduction.

GEHC. At about $70, GE HealthCare trades near 16x trailing and 13x forward earnings and about 11x EV/EBITDA, below where it stood at the start of 2026 after the shares fell about 15% year to date. Investors weigh steady diagnostics demand, recurring service revenue and AI-driven upgrades against hospital capital-spending cycles and spinoff debt. Q3 results on October 28 are expected to show EPS near $1.21; the 20-analyst mean target is about $83.

Headline figures (approximate, October 2026): BAYRY shows revenue (fy2025) ~EUR 45.6 billion (~$51 billion), ebitda before special items (fy2025) ~EUR 9.7 billion; 2026 guide ~EUR 9.6 to 10.1 billion, core eps guidance (2026) ~EUR 4.10 to 4.80 per share (new methodology), share price ~EUR 44 on Xetra; BAYRY ~$12.2 (4 ADRs = 1 share); GEHC shows revenue (ttm) ~$21.3 billion, revenue growth (q2 2026, yoy) ~6%, operating margin ~15%, net income (ttm) ~$2.0 billion.

BAYRY and GEHC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAYRY and GEHC exposure against your real portfolio. It is not an investment adviser.